SC
ADVM

Skylands Capital’s Adverum Biotechnologies ADVM Stock Holding History

Skylands Capital’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,000
Closed -$487K – 219
2015
Q2 		$487K Buy
+3,000
New +$1.01M 0.05% 187

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Skylands Capital's ADVM Position: Q3 2015 in Review

Skylands Capital sold out of Adverum Biotechnologies (ADVM) in Q3 2015, closing a stake of 3,000 shares — an estimated $487K sold.

Skylands Capital first reported a position in ADVM in Q2 2015 and held it in 1 quarter. The position peaked at $487K in Q2 2015. 92 funds tracked by Wall St. Rank hold ADVM as of Q3 2015.

  • Skylands Capital reported no remaining Adverum Biotechnologies position as of Q3 2015 after selling out during the quarter.
  • Skylands Capital sold 3,000 Adverum Biotechnologies shares in Q3 2015, an estimated $487K.
  • Skylands Capital first reported a position in Adverum Biotechnologies in Q2 2015 and held it in 1 quarter.
  • Skylands Capital's Adverum Biotechnologies position peaked at $487K in Q2 2015.
  • 92 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2015.

Based on Skylands Capital's 13F filing for Q3 2015, filed 14 Oct 2015.